JP2020528750A5 - - Google Patents

Download PDF

Info

Publication number
JP2020528750A5
JP2020528750A5 JP2020503984A JP2020503984A JP2020528750A5 JP 2020528750 A5 JP2020528750 A5 JP 2020528750A5 JP 2020503984 A JP2020503984 A JP 2020503984A JP 2020503984 A JP2020503984 A JP 2020503984A JP 2020528750 A5 JP2020528750 A5 JP 2020528750A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
pharmaceutical composition
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020503984A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020528750A (ja
JP7296363B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/043936 external-priority patent/WO2019023482A1/en
Publication of JP2020528750A publication Critical patent/JP2020528750A/ja
Publication of JP2020528750A5 publication Critical patent/JP2020528750A5/ja
Priority to JP2023095262A priority Critical patent/JP2023113893A/ja
Application granted granted Critical
Publication of JP7296363B2 publication Critical patent/JP7296363B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020503984A 2017-07-27 2018-07-26 抗ctla-4抗体およびその使用 Active JP7296363B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023095262A JP2023113893A (ja) 2017-07-27 2023-06-09 抗ctla-4抗体およびその使用

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762537753P 2017-07-27 2017-07-27
US62/537,753 2017-07-27
US201762588853P 2017-11-20 2017-11-20
US62/588,853 2017-11-20
US201862645284P 2018-03-20 2018-03-20
US62/645,284 2018-03-20
US201862685599P 2018-06-15 2018-06-15
US62/685,599 2018-06-15
PCT/US2018/043936 WO2019023482A1 (en) 2017-07-27 2018-07-26 ANTI-CTLA-4 ANTIBODIES AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023095262A Division JP2023113893A (ja) 2017-07-27 2023-06-09 抗ctla-4抗体およびその使用

Publications (3)

Publication Number Publication Date
JP2020528750A JP2020528750A (ja) 2020-10-01
JP2020528750A5 true JP2020528750A5 (cg-RX-API-DMAC7.html) 2021-08-26
JP7296363B2 JP7296363B2 (ja) 2023-06-22

Family

ID=63165545

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020503984A Active JP7296363B2 (ja) 2017-07-27 2018-07-26 抗ctla-4抗体およびその使用
JP2023095262A Pending JP2023113893A (ja) 2017-07-27 2023-06-09 抗ctla-4抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023095262A Pending JP2023113893A (ja) 2017-07-27 2023-06-09 抗ctla-4抗体およびその使用

Country Status (17)

Country Link
US (3) US10844137B2 (cg-RX-API-DMAC7.html)
EP (1) EP3658585A1 (cg-RX-API-DMAC7.html)
JP (2) JP7296363B2 (cg-RX-API-DMAC7.html)
KR (1) KR102710122B1 (cg-RX-API-DMAC7.html)
CN (1) CN111133004B (cg-RX-API-DMAC7.html)
AU (1) AU2018307675B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020001266A2 (cg-RX-API-DMAC7.html)
CL (1) CL2020000216A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020000438A2 (cg-RX-API-DMAC7.html)
IL (1) IL271882B2 (cg-RX-API-DMAC7.html)
MA (1) MA49687A (cg-RX-API-DMAC7.html)
MY (1) MY202870A (cg-RX-API-DMAC7.html)
PH (1) PH12020500078A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202000366WA (cg-RX-API-DMAC7.html)
TW (1) TWI799432B (cg-RX-API-DMAC7.html)
WO (1) WO2019023482A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202000113B (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL307242B1 (en) 2016-12-07 2026-07-01 Agenus Inc Anti-CTLA-4 antibodies and methods of using them
TWI799432B (zh) * 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途
TWI850282B (zh) 2018-11-27 2024-08-01 香港商弘年發展有限公司 用於治療癌症之質體建構體和使用方法
WO2020127377A1 (en) 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
CN114008071B (zh) 2018-12-27 2025-01-21 吉加根公司 抗ctla-4结合蛋白及其使用方法
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
MA55204A (fr) * 2019-03-06 2022-01-12 Regeneron Pharma Inhibiteurs de la voie il-4/il-13 pour une efficacité améliorée dans le traitement du cancer
MA55316A (fr) 2019-03-13 2022-01-19 Merck Sharp & Dohme Polythérapies anticancéreuses comprenant des agents de blocage de ctla-4 et pd-1
EP4054723A1 (en) 2019-11-08 2022-09-14 Bristol-Myers Squibb Company Lag-3 antagonist therapy for melanoma
TW202136287A (zh) 2019-12-17 2021-10-01 法商Ose免疫治療公司 包含il-7變體之雙官能分子
JP2023510132A (ja) * 2019-12-20 2023-03-13 メルク・シャープ・アンド・ドーム・エルエルシー Pd-1アンタゴニスト、ilt4アンタゴニストおよび化学療法剤の組合せを使用して癌を治療する方法
EP4139440B1 (en) 2020-04-22 2026-08-19 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
TW202216771A (zh) * 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體
US20230265192A1 (en) * 2020-07-02 2023-08-24 Gigagen, Inc. Anti-ctla-4 binding proteins and methods of use thereof
CA3185091A1 (en) * 2020-07-08 2022-01-13 Yuan Cheng Stabilized formulations containing anti-ctla-4 antibodies
CA3195019A1 (en) 2020-10-06 2022-04-14 Maria Fardis Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022112198A1 (en) 2020-11-24 2022-06-02 Worldwide Innovative Network Method to select the optimal immune checkpoint therapies
WO2022127882A1 (zh) * 2020-12-17 2022-06-23 南京蓬勃生物科技有限公司 筛选靶向CD47-SIRPα免疫检查点的候选药物的方法和试剂盒
JP2023554395A (ja) 2020-12-17 2023-12-27 アイオバンス バイオセラピューティクス,インコーポレイテッド Ctla-4及びpd-1阻害剤と併用した腫瘍浸潤リンパ球療法による治療
EP4314253A2 (en) 2021-03-25 2024-02-07 Iovance Biotherapeutics, Inc. Methods and compositions for t-cell coculture potency assays and use with cell therapy products
EP4320156A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
MX2023011964A (es) 2021-04-09 2024-01-08 Ose Immunotherapeutics Nuevo andamio para moléculas bifuncionales con propiedades mejoradas.
WO2022245820A1 (en) 2021-05-17 2022-11-24 Emory University Vasoactive intestinal peptide (vip) receptor antagonists
MX2024004429A (es) * 2021-10-29 2024-05-06 Oncoc4 Inc Regimenes de dosificacion del anticuerpo anti-ctla-4.
MX2024006187A (es) 2021-11-24 2024-08-14 Regeneron Pharma Métodos para tratar el cáncer con anticuerpos biespecíficos anti-cd3 x muc16 y anticuerpos anti-ctla-4.
CN118541390A (zh) * 2022-01-30 2024-08-23 百奥赛图(北京)医药科技股份有限公司 抗ctla4/ox40双特异性抗体及其用途
EP4507704A1 (en) 2022-04-15 2025-02-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
WO2024003360A1 (en) 2022-07-01 2024-01-04 Institut Curie Biomarkers and uses thereof for the treatment of neuroblastoma
EP4565610A1 (en) 2022-08-02 2025-06-11 Ose Immunotherapeutics Multifunctional molecule directed against cd28
WO2024112571A2 (en) 2022-11-21 2024-05-30 Iovance Biotherapeutics, Inc. Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
WO2024200820A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Method of synthesis of targeted lipid nanoparticle and uses thereof
JP2026512425A (ja) 2023-03-30 2026-04-16 オーエスイー・イミュノセラピューティクス 免疫細胞増強分子の発現のための活性化免疫細胞に標的化された脂質ベースのナノ粒子及びその使用
EP4727974A1 (en) * 2023-06-16 2026-04-22 Genor Biopharma Co., Ltd. Anti-ccr8 antibody and anti-ccr8/ctla4 bispecific antibody
WO2025140478A1 (zh) * 2023-12-29 2025-07-03 百奥泰生物制药股份有限公司 抗pd-l1/cd47双特异抗体在联合用药中的应用
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2026068705A1 (en) 2024-09-26 2026-04-02 Ose Immunotherapeutics Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
ES2706547T3 (es) * 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
WO2009100140A1 (en) * 2008-02-04 2009-08-13 Medarex, Inc. Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
GB201103955D0 (en) * 2011-03-09 2011-04-20 Antitope Ltd Antibodies
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗pd-l1之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
AU2015229591B2 (en) * 2014-03-11 2020-10-22 Regeneron Pharmaceuticals, Inc. Anti-EGFRvlll antibodies and uses thereof
TWI754319B (zh) * 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
CN114014930A (zh) 2015-02-13 2022-02-08 索伦托药业有限公司 结合ctla4的抗体治疗剂
DK3303394T3 (da) * 2015-05-29 2020-07-06 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
WO2017084078A1 (en) * 2015-11-19 2017-05-26 Zeling Cai Ctla-4 antibodies and uses thereof
KR102209364B1 (ko) * 2016-12-09 2021-02-01 리제너론 파아마슈티컬스, 인크. T 세포 수용체를 시퀀싱하기 위한 시스템 및 방법 및 이의 용도
TWI799432B (zh) * 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途

Similar Documents

Publication Publication Date Title
JP2023113893A5 (cg-RX-API-DMAC7.html)
JP2024037894A5 (cg-RX-API-DMAC7.html)
IL276830B1 (en) Anti-claudin 18.2 antibodies and their uses
RU2018145852A (ru) Антитело против lag-3, его антигенсвязывающий фрагмент и их фармацевтическое применение
JP2022526764A5 (cg-RX-API-DMAC7.html)
JP2021514664A5 (cg-RX-API-DMAC7.html)
JP2021531005A5 (cg-RX-API-DMAC7.html)
JP2021527431A5 (cg-RX-API-DMAC7.html)
JP2020534250A5 (cg-RX-API-DMAC7.html)
FI3932951T3 (fi) Menetelmiä ihosyövän hoitamiseksi antamalla PD-1-inhibiittoria
RU2018119165A (ru) Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение
JP2017535257A5 (cg-RX-API-DMAC7.html)
RU2016104880A (ru) Способы лечения рака с использованием антагонистов, связывающих с осью pd-1, и ингибиторов tigit
JP2019503361A (ja) がんを治療するための抗pd−1抗体と二重特異性抗cd20/抗cd3抗体の組合せ
RU2019104980A (ru) Анти-icos антитела
RU2017118225A (ru) Антитела к PD-1 и способы их применения
JP2023543152A5 (cg-RX-API-DMAC7.html)
JP2017512759A5 (cg-RX-API-DMAC7.html)
JP2022512750A5 (cg-RX-API-DMAC7.html)
JP2020522280A5 (cg-RX-API-DMAC7.html)
JP2020522281A5 (cg-RX-API-DMAC7.html)
RU2017114968A (ru) Связывающие молекулы, а именно антитела, способные связываться с l1cam (cd171)
JP2022526841A5 (cg-RX-API-DMAC7.html)
WO2023040940A1 (zh) Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症
JP2021512652A5 (cg-RX-API-DMAC7.html)